Fractyl (GUTS) Q3 2025 Earnings Call Transcript

Image source: The Motley Fool.

DATE

Wednesday, November 12, 2025 at 4:30 p.m. ET

CALL PARTICIPANTS

• Chief Executive Officer — Harith Rajagopalan, M.D., Ph.D.
• Chief Financial Officer — Lisa A. Davidson

Need a quote from a Motley Fool analyst? Email pr@fool.com

TAKEAWAYS

• Revita REMAIN Clinical Results -- In the REMAIN one midpoint cohort, Revita-treated patients achieved an additional 2.5% total body weight loss at three months post-tirzepatide discontinuation, while sham patients regained about 10%, with statistical significance and no serious adverse events reported.
• Durability Data -- In the German real-world registry, patients with two-year follow-up maintained an average total body weight loss of 8.92% at two years (up from 8% at one year) and achieved a 1.7% reduction in HbA1c, despite a net reduction in medications.
• Pivotal Cohort Progress -- As of October 31, over 60% of the pivotal REMAIN one cohort participants had been randomized, with full randomization of 315 patients expected early next year.
• Upcoming Catalysts -- Key milestones include REVEAL one six-month data this quarter, REMAIN one midpoint cohort six-month data in 2026, and potential PMA submission based on top-line pivotal data in 2026.
• Financial Position -- As of September 30, 2025, cash and cash equivalents totaled $77.7 million; proceeds from $83 million in recent public offerings extend the cash runway into early 2027.
• Operating Expenses -- Research and development expenses were $17.5 million compared to $19 million in the prior-year quarter, mainly due to decreased spending on the REVITALIZE one study and lower stock-based compensation, partially offset by REMAIN one pivotal and Rejuva program investments; selling, general, and administrative expenses rose to $5.2 million from $4.8 million, primarily reflecting warrant-related costs.
• Net Loss -- Net loss for the quarter was $45.6 million versus $23.2 million in the corresponding 2024 period, with the increase driven by a $23.5 million non-cash accounting change related to warrant fair value.
• Market Opportunity -- Revita’s market potential was described as approaching 1,000,000 peak annual procedures, with economic incentives for clinical adoption at participating centers and gross margins potentially comparable to or better than other advanced endoscopic interventions.
• Rejuva-002 Preclinical Data -- New preclinical results for Rejuva-002 showed nearly 30% body weight loss after a single dose in an obesity model, with no observed adverse effects reported.
• Rejuva-001 Status -- All preclinical CMC and lot release steps for Rejuva-001 are complete, supporting the first patient dosing and preliminary data anticipated in 2026.
• Standardized Lifestyle Protocol -- All clinical trial participants received standardized diet and exercise recommendations modeled after semaglutide and tirzepatide Phase 3 protocols, including a 500 kcal/day deficit and 30-40 minutes of exercise three to four times weekly.
• Payer and Reimbursement Work -- There are no existing CPT codes for Revita, and the company is actively engaged in developing a U.S. reimbursement strategy prior to approval.

SUMMARY

Pivotal enrollment for the REMAIN one cohort is proceeding ahead of schedule, establishing a clear timeline for full randomization and upcoming top-line data. Real-world durability evidence from Germany demonstrated sustained efficacy at two years, reinforcing Revita’s differentiated value proposition in managing obesity and type 2 diabetes. Robust preclinical progress for Rejuva-001 and Rejuva-002 signaled advancement toward clinical translation and expanded pipeline visibility beyond the core Revita program.

• Management said, "we expect our cash runway to extend into early 2027," highlighting funding sufficiency through multiple major clinical and regulatory milestones.
• Rajagopalan stated, "there's absolutely no waning of effect between one year and two years." in the German registry study, emphasizing consistency of long-term outcomes.
• The company positioned Revita as a complementary option to GLP-1 therapies for post-drug weight maintenance, targeting the anticipated demand as millions discontinue pharmacologic treatment.
• Management committed to providing further updates on reimbursement and market access strategy at the next earnings call, with no current procedural coding established for Revita.

INDUSTRY GLOSSARY

• Revita DMR System (Revita): Endoscopic device-based procedure designed to remodel the duodenal lining to improve metabolic control in obesity and type 2 diabetes.
• GLP-1 therapy: Glucagon-like peptide-1 agonist drugs used in diabetes and obesity management to promote weight loss and glycemic control.
• PMA (Pre-Market Approval): U.S. Food and Drug Administration regulatory submission process for medical devices requiring evidence of safety and effectiveness.
• CMC: Chemistry, Manufacturing, and Controls—a regulatory standard referring to quality requirements for pharmaceutical products in clinical development.
• CPT codes: Current Procedural Terminology codes used for medical billing and insurance reimbursement in the United States.

Full Conference Call Transcript

Harith Rajagopalan: Thank you, Brian. Good afternoon, everyone. This quarter marked a major inflection point for Fractyl Health, Inc. Common Stock. We delivered the first randomized double-blind sham-controlled data showing that a single Revita procedure can sustain weight loss after GLP-1 drug discontinuation. We believe Revita addresses one of the most urgent challenges in obesity, which is how to maintain success once therapy stops. We also strengthened our balance sheet to support our upcoming clinical and regulatory milestones into early 2027. And we continue to advance our clinical programs ahead of schedule, setting the stage for a series of important catalysts in weight maintenance over the next several quarters.

Across every front—clinical, regulatory, and financial—we are building momentum toward what I believe will be the most exciting and definitional twelve months in our company's history. The science is working, the data are strong, and the opportunity ahead of us has never been clearer.

Let's start with Revita. Revita is our endoscopic procedural therapy designed to remodel the duodenal lining by hydrothermal ablation to address a root cause of metabolic disease. Revita resets the gut's metabolic control system in the duodenum, which is a key site of nutrient sensing and signaling in the gut and is hardwired to the brain through a key gut-brain connection that controls body weight and blood sugar. Decades of high-fat and high-sugar diets can damage this duodenal lining, disrupt gut-brain signaling, and drive hunger and insulin resistance. Revita is designed to remove this damaged tissue and allow a healthy new lining to regrow, restoring normal gut-brain signaling and metabolic balance. It's like LASIK for obesity.

Since enrolling the first patients in our REMAIN weight maintenance program in August 2024, the last five quarters have been a period of incredible clinical operational execution and momentum. In September, we reported three-month data from the REMAIN one midpoint cohort. Revita-treated patients lost an additional 2.5% total body weight, while patients in the sham group regained about 10%—a statistically significant and clinically meaningful separation after the discontinuation of tirzepatide. The procedure was well tolerated with no related serious adverse events. These results not only materially de-risk the pivotal readout ahead, but they also represent a true turning point in metabolic medicine.

If Revita continues to sustain weight loss at six and twelve months, in line with the durability we have seen across prior clinical studies involving hundreds of patients with Revita, we believe we will have a transformative new treatment option in obesity.

Enrollment in our REMAIN one pivotal cohort was complete in Q2, and randomizations in that cohort are progressing ahead of schedule. As of October 31, we have randomized over 60% of the pivotal cohort patients, and we are on track to complete randomization of the full 315 participants early next year. This pivotal study has advanced ahead of plan from the outset, and we are executing it with the focus and precision that this opportunity deserves. Looking ahead, we expect a rich set of value-creating catalysts in the coming quarters: six-month data from the REVEAL one open-label cohort this quarter, six-month randomized data from the REMAIN one midpoint cohort in 2026, and top-line pivotal data and potential PMA submission in 2026.

Based on prior Eli Lilly studies, patients who stop GLP-1 therapy typically regain about 10% of their body weight by six months. We believe that Revita can be a highly successful therapy if it cuts the rate of weight regain in half, so roughly less than a five percentage point weight regain at six months, which would represent a clinically meaningful and substantial benefit for patients and a strong validation of Revita's potential. We believe Revita is defining a new therapeutic category in obesity—post-GLP-1 weight maintenance—a category that complements, not competes with, chronic drug therapy and provides the off-ramp that patients and physicians have been waiting for. Millions of Americans are expected to discontinue GLP-1 therapy over the next year.

Every one of them will face the challenge of keeping the weight off. Revita is built for that moment.

Durability is central to Revita's value and a huge advantage compared to chronic pharmacology. And we continue to see encouraging real-world durability outcomes in Revita clinical studies, including in Germany. In our German real-world registry study, thirty patients have now reached one year of follow-up, and fourteen patients have reached two years of follow-up. The first fourteen patients with two years of follow-up maintained an average total body weight loss of 9% and a 1.7% reduction in HbA1c in a patient population with advanced type 2 diabetes despite a net reduction in medications. Three-month results were highly predictive of six, twelve, and twenty-four-month results.

These durable outcomes not only strengthen our confidence as we move toward a pivotal readout in REMAIN one, but also underscore Revita's potential to deliver long-lasting benefit in real-world settings.

By this time next year, we expect to have one-year open-label data in weight maintenance, top-line data from our REMAIN one pivotal cohort, and a larger sample of patients with two-year data and beyond from our German real-world registry study. Taking these clinical proof points together, we believe Revita will have a compelling and comprehensive clinical data package that will be ready for both regulatory filings and reimbursement discussions by the second half of next year. Revita's durable activity also drives its economic rationale.

By potentially reducing the need for ongoing drug therapy and reducing the risk of downstream adverse health outcomes, it offers a multiyear health and cost advantage for payers who are seeking sustainable alternatives to chronic GLP-1 treatment.

In light of this, we are encouraged by the recent announcement from the US government on GLP-1 access in Medicare. Expanding access to these medicines is good for patients, and it's good for the field. More patients starting GLP-1s, either as injectables or as orals, also means more patients will eventually need an off-ramp when most inevitably discontinue treatment. Our clinical work and our relationships have also positioned us well for rapid activation once Revita is approved. Many of the physicians participating in our clinical studies are experienced users of the procedure, committed to treating obesity and metabolic disease with their endoscopic skills, and they are based at leading centers across the country.

Already active at major clinical centers from Miami to Seattle, from New England to Southern California, and together with partners like Berry Endo, we have already established and have a ready-to-activate footprint at several of the highest-volume endoscopy centers in the US. This enables, in our view, a targeted and efficient commercial model for us or our partners to access upon approval.

Our market analysis confirms the size and strength of this opportunity. Because the procedure fits naturally into an existing endoscopy workflow, Revita could reach nearly 1,000,000 annual procedures at peak adoption, translating to a sizable revenue opportunity. Importantly, Revita's unit economics create strong incentives for adoption at the clinical site level. We expect gross margins for participating centers to be comparable to or better than other advanced endoscopic interventions, creating meaningful financial alignment between clinical and commercial stakeholders. Taking a step back, what we are talking about is potentially the first scalable therapy that addresses a root cause of obesity and type 2 diabetes and can change the trajectory of both diseases.

If Revita is successful in post-GLP-1 weight maintenance, a hard-to-treat and high unmet need patient segment, we believe it can be effective across the spectrum of metabolic disease—not only for maintenance but also as frontline, not only as a standalone therapy but also in combination with weight loss medications.

Turning to Rejuva now. Our smart GLP-1 platform, we continue to make exciting progress. Earlier this month, we presented new preclinical data from Rejuva-002, our candidate for obesity, which showed nearly 30% body weight loss after a single dose in a translational obesity model with no observed adverse effects. Rejuva-001, our lead candidate in type 2 diabetes, is designed to reprogram pancreatic islet cells to secrete GLP-1 in response to glucose with the goal of restoring physiologic hormone regulation and achieving long-term metabolic remission. We have now completed our preclinical CMC and lot release for our Rejuva-001 drug product.

And with all preclinical milestones now checked off, we remain on track to dose the first patients and report preliminary data in 2026.

Between Revita and Rejuva, complementary endoscopic approaches designed to reset the gut and reprogram the pancreas, we are building a platform that can fundamentally change how metabolic diseases are treated. Our differentiation is our strength. Our product candidates are designed to do what the majority of patients need but current therapies cannot deliver: durable, physiologic, and designed to work with the body, not against it. Now let me hand it to Lisa to discuss our financials.

Lisa A. Davidson: Thank you, Harith. Turning now to our financial results for 2025. For the quarter ended September 30, research and development expenses were $17.5 million compared to $19 million for the same period in 2024. The decrease was primarily due to reduced spending on the REVITALIZE one study and lower stock-based compensation expense, partially offset by continued investment in the REMAIN one pivotal study and Rejuva program. Selling, general, and administrative expenses were $5.2 million compared to $4.8 million in the third quarter of last year. The year-over-year increase primarily reflected one-time costs associated with the issuance of warrants in connection with our August underwritten public offering.

We reported a net loss of $45.6 million compared to $23.2 million in the same period of 2024. The variance was largely driven by a $23.5 million non-cash accounting change in the fair value of warrants and does not reflect a change in our underlying operating performance.

As of September 30, 2025, we had approximately $77.7 million in cash and cash equivalents. With the proceeds from our recent $83 million in underwritten offerings, we expect our cash runway to extend into early 2027, funding key milestones, including six-month randomized data from the REMAIN one midpoint cohort, top-line pivotal data, and our potential PMA submission. Overall, we remain in a strong financial position, well-capitalized to advance our strategic and clinical priorities in the quarters ahead. Back to you, Harith.

Harith Rajagopalan: Thank you, Lisa. As we look ahead, the path for Fractyl Health, Inc. Common Stock is clear and compelling. Within the next twelve months, we expect multiple catalysts that will transform the company: REVEAL one six-month data in Q4, REVEAL one-year data in Q2, REMAIN one midpoint six-month data in Q1, top-line pivotal data, and potential PMA submission of our PMA to the FDA both in H2 2026, all funded by a strong balance sheet that extends to early 2027. Each of these milestones moves us closer to delivering a first-in-class durable, non-drug solution for obesity and type 2 diabetes.

With those catalysts ahead, our growing body of data, expanding clinical footprint, and strengthened balance sheet, we are entering 2026 with confidence, clarity, and purpose. I am incredibly proud of how far we have come, and I am more excited than ever about where we are headed.

With that, I would like to thank the people who make this work possible. To our employees, thank you for your relentless drive and belief in our mission. To the physicians and investigators advancing our clinical programs with care and commitment, we are proud to partner with you. And to the patients participating in our trials, thank you for your courage and your trust. To our investors, thank you for your continued support and conviction. Together, we are building what comes next in metabolic medicine. Operator, we are now ready to take questions.

Operator: Thank you. At this time, we will conduct a question and answer session. As a reminder, to ask a question, you will need to press 11 on your phone and wait for your name to be announced. To withdraw your question, please press 11 again. Please stand by while we compile the Q&A roster. Our first question comes from the line of Jason Gerberry from Bank of America Securities. Your line is now open.

Jason Gerberry: Hey. This is Chi on for Jason. Thanks for taking our question. I guess, Harith, could you just walk us through what you are looking for with the six-month update for REVEAL one in Q4 and also the six-month update for REMAIN one midpoint in Q1? As you think about, you know, looking at Revita's profile as it pertains to, say, durability of benefit. Thank you.

Harith Rajagopalan: Sure, Chi. Thanks for the question. The six-month REVEAL data set coming up later this quarter will be our first look at patients six months after stopping a GLP-1-based therapy and then undergoing the procedure. We have hundreds of patients' worth of experience in type 2 diabetes with Revita as a primary therapy, all of which have shown that one and three-month results are excellent predictors of durability at six, twelve, and twenty-four months. And so our hope would be to see a similar consistency of results between three months and six months. Based on Surmount four's tirzepatide data, where tirzepatide was withdrawn, patients typically regained about 10% of their body weight within six months after discontinuing treatment.

So looking at REVEAL and REMAIN upcoming six-month data, if Revita patients are able to regain less than half of that body weight or less than 5% total, that would be a very compelling outcome and a very strong signal heading into the pivotal trial. Remember that six months is important because it is also the timing of the pivotal trial's primary endpoint. And so because of the fact that our REVEAL open-label data at three months translated to the REMAIN randomized data at three months, we are very hopeful and optimistic that the six-month data from REVEAL and the REMAIN midpoint will translate very directly to positive read-through for the full pivotal study whose data are expected next year.

Chi: Yeah. That sounds great. If I may squeeze one in, it looks like the pivotal cohort for REMAIN one is randomizing ahead of schedule. It looks like you are expecting randomization to complete in early 2026. And as we think about the primary analysis being six months, should we expect, you know, potentially a readout early part of the second half of 2026?

Harith Rajagopalan: Yeah. That is a very reasonable expectation, Chi. We are heading towards completing randomizations early in '26. The last patient visit, we expect very early in the latter half of the year. And so we feel very confident based on where we sit today in the timing of our pivotal top-line readout and PMA submission both in '26. And I will also say that while we've, as I mentioned, completed randomization in over 60% of the patients as of October, we are randomizing every single day, every single workday, and we have good line of sight to the completion of randomizations early in '26.

Chi: Alright. Thanks so much.

Harith Rajagopalan: Thank you. Thank you. One moment for our next question.

Operator: Our next question comes from the line of Umer Raffat from Evercore. Your line is now open.

Mike DiFiore: Hi, guys. This is Mike DiFiore in for Umer. Thanks so much for taking my question and congrats on the continued progress. A few for me. On Revita, just would like some clarity on the German registry data where you said that patients have maintained an average total body weight loss of around 9%. And my question is, in the 14 patients that have reached two years of follow-up, what was their average weight loss at one versus two years? I just kind of want to get a sense if efficacy has waned at all in this specific subset of patients. Then I have a follow-up.

Harith Rajagopalan: Sure. The answer is there's absolutely no waning of effect between one year and two years. In fact, I believe that there is a slightly greater weight loss at two years than one year. The numbers I have in front of me are 8% weight loss at one year and 8.92% weight loss at two years. I want to put this in context. If I may. These are patients with advanced type 2 diabetes. Their BMI was 32. They are mostly men. That means these are the people who are hardest in whom to achieve weight loss.

And what that 9% means is that you are achieving very significant and clinically meaningful and sustained weight loss maintenance in a population of individuals in whom it is very, very hard to get any weight loss at all. In addition, the large improvements in hemoglobin A1c in these patients actually tend to translate to harder-to-achieve weight loss as well. So all of this was seen in the context of a substantial reduction in hemoglobin A1c and a significant net reduction in medication utilization. In fact, I suspected, Mike, that you were gonna ask me a question about GLP-1 use and not.

And what I will tell you is there is less medication utilization at two years than there is at the start of the study. And if you censor out the small number of patients who are on more medicines, the treatment effect is unchanged in the overall cohort. And so we feel very, very confident about what this means for Revita's clinical profile, both from a potency and from a durability standpoint. We think this translates directly to what you might expect to see in how REMAIN will perform in terms of both of those dimensions.

And we think that payers will really care that Revita can do something reliably in the real world, which we know is a major problem in the obesity landscape today, where real-world results with most of the modern pharmacology are woefully underperforming relative to what Phase 3 showed because of treatment discontinuation, undertitration, and other factors that limit the effect of these medicines in the real world.

Mike DiFiore: Excellent. Thanks so much for the color, Harith. Very, very helpful. And just a follow-up on Rejuva-002 for obesity. Just curious at this point if you're able to disclose the relative GLP versus GIP receptor potency and affinities? And also, what would be the average circulating active GLP levels in mice? Would it be greater than the 10 to 20 picomolar levels that have been seen with the Rejuva-001? Thank you.

Harith Rajagopalan: So with respect to the relative GIP versus GLP ratios, this is something that we have actively optimized and have data on, but we have not shared publicly. But we do know that certain ratios work better than others. Happy to disclose that. We haven't yet compiled the GLP-1 circulating levels, but it's an opportunity for me to pivot to talking about the GLP-1 levels with Rejuva-001, which is soon to enter the clinic.

We were just coming out of Obesity Week and having a number of interesting conversations with obesity experts, and we have a fascinating and incredibly compelling aspect to Rejuva-001 in that we have drug-like efficacy with one-tenth the circulating GLP-1 levels that are normally seen with these medicines. Which implies we can achieve the efficacy and potency of these medicines and, in some cases, exceed it, but are expecting far less in terms of tolerability issues because it's acting through more endogenous means locally in the gut rather than hitting the brain's CNS receptor, which is where tolerability issues arise with current pharmacology.

Mike DiFiore: Great. Thank you.

Harith Rajagopalan: Thank you.

Operator: Thank you. One moment for our next question. Our next question comes from the line of Mike Ulz from Morgan Stanley. Your line is now open.

Mike Ulz: Good afternoon and thanks for taking the question. Maybe just to follow-up on the Revita durability question for the German registry. You know, it looks like up to two years, you're seeing a nice durable effect there. Just curious what the variability is among the patients and how tight that is. Thanks.

Harith Rajagopalan: It's remarkably consistent, I've gotta say, Mike. I will follow-up on some more detail on that, but you can just tell from the error bars in the graph that is in our updated corporate deck that the vast majority of patients who lose weight at three months maintain that body weight loss all the way through one year, and the error bars are not really getting wider over time, which tells us that there is a remarkable consistency to the weight loss maintenance here. It's very encouraging for us as a signal. And let's just say we are continuing to follow these patients so we have a nice sample of patients at one year and two years.

And if you roll the clock forward, we're excited about the ongoing demonstration of durability entering into 2026 as we continue to follow these patients.

Mike Ulz: Great. That's helpful. And then maybe just to follow-up on Rejuva and assuming you get the CTA cleared and you start the study next year, you mentioned potential for some preliminary data. Maybe just talk a little bit about what might be included in that preliminary data.

Harith Rajagopalan: Well, we're focusing first and foremost on feasibility, safety, and preliminary PK and PD profiles. And so I think that as we enter into the new year, once the CTA is approved and we have crystal clarity on when the first patients will be dosed, I'd be happy to answer that question for you.

Mike Ulz: Great. Thank you.

Harith Rajagopalan: Thank you.

Operator: Thank you. One moment for our next question. Our next question comes from the line of Whitney Ijem from Canaccord Genuity. Your line is now open.

Angela: Hi, guys. This is Angela on for Whitney. Thanks for taking our question, and congrats on all the progress. Just one from us, can you remind us, are there diet and lifestyle measures taken for patients after they receive the Revita procedure in the studies? Are they getting counseling or are they following a program?

Harith Rajagopalan: There are diet and lifestyle measures. They start when patients enroll in the trial even before they begin tirzepatide in the open-label run-in phase, and they continue all the way through the end of the study. So there is no change to the diet and lifestyle per se at the time of Revita. It's an ongoing standardized diet and lifestyle recommendation. And those who are providing that recommendation are blinded to treatment allocation.

Angela: Got it. Are you able to disclose what those measures are?

Harith Rajagopalan: Yeah. We modeled it after very much what the semaglutide and tirzepatide Phase 3 studies used, which is a 500 kilocalorie net calorie deficit every day and thirty to forty minutes of exercise three to four times a week, roughly.

Angela: Great. Thank you so much.

Harith Rajagopalan: Yep.

Operator: Thank you. One moment for our next question. Our next question comes from the line of Jeffrey Cohen from Ladenburg. Your line is now open.

Jeffrey Cohen: Hey, Harith and Lisa. Hope you're well. Just two questions for me. So I guess firstly, Harith, could you talk about—I hate to go back to the German study—were those patients type ones or type twos, and what percent were on pumps versus MDIs?

Harith Rajagopalan: Those patients were type 2 diabetics, Jeff, and most of them were on non-insulin medications. They were on an average of one to three medications. Only a small number were on insulin. But what we are seeing is consistent data independent of the background medication. The single biggest determinant of effect for Revita, both on weight and on blood sugar, is whatever their baseline weight and blood sugar was rather than their background medicine.

Jeffrey Cohen: Okay. That's helpful. Thank you. Then secondly here, I know we talked about it earlier, but could you talk about CPT codes and how the payers are thinking about the procedure? I know there's been some changes on some codes, particularly in ablation and argon plasma.

Harith Rajagopalan: Sure. There are no CPT codes today for the Revita procedure. And we are actively working with reimbursement and market access experts on developing a roadmap towards establishing CPT coding ahead of approval in the United States. We will have more to share on the specifics of our reimbursement strategy at our next earnings call.

Jeffrey Cohen: Perfect. Thanks for the color. I appreciate it. Good quarter.

Harith Rajagopalan: Thank you.

Operator: Thank you. One moment for our next question. Our next question comes from the line of Joe Pantginis from H.C. Wainwright. Your line is now open.

Joe Pantginis: Hey. Good afternoon, everyone. Thanks for taking the question. And I promise I won't be typing during your answers. So first, with regard to the comments that you made, obviously, from Lilly, historical data, the patients regaining about 10% of their weight over six months, I just want to get some clarity or even a reminder that, you know, following the midpoint, three-month data, how these patients in the sham group fared, you know, based on the recovery of the liver, the Lilly data, the comparison.

Harith Rajagopalan: Well, as you know, and I appreciate the question, Joe. In our midpoint cohort, patients who had lost 18% of body weight while on tirzepatide regained 10% of that body weight in the sham arm by three months. I told you that tirzepatide data from Lilly suggest 10% weight regain by six months. So we saw a little bit more of that in the midpoint cohort than what Lilly showed. A couple of points. We're generating new data here because what we have done is we've taken tirzepatide. We are choosing only patients who have achieved at least 15% body weight loss, and we're choosing those patients who get there quickly.

Both the size and the speed of weight loss are thought to also correlate with the size and speed of weight regain. So one of the cruel aspects of starting and stopping GLP-1s is that the more effective and rapidly the drug works, the more vicious the rebound will be. As the drugs get better, as you go from tirzepatide to even whatever comes next, and you start hearing about drugs achieving greater and greater weight loss, you can immediately interpret that is likely to mean that the rebound of weight regain will be that much more violent and severe.

We would expect in our midpoint cohort and in our pivotal cohort a more or less linear rate of weight regain over the three to six to twelve-month period of time. And we ourselves are incredibly interested to see what that weight picture will look like at six and twelve months. But the best data we have, as I said, is 10% regain at six months from Lilly's own data. Really appreciate you highlighting that as part of the process.

Joe Pantginis: And then, sticking with Revita, and my last question is how would you sort of define your needs nearer term and intermediate term with regard to manufacturing needs and expansion?

Harith Rajagopalan: Well, in the near term, we feel very good about our ability to support the clinical study, and we are now turning our attention with the excellent data that we just shared to ensuring that we have adequate manufacturing to be ready for scale. Just as a reminder for people, we do all final assembly and testing of our Revita catheter in our facility. And we have ample capacity to support our anticipated volumes for the coming years. But I should also say that we have subassemblies of our catheter that are currently manufactured by tier-one contract manufacturers. They could assume larger and larger responsibilities in order to help us make sure that we meet the demand in the market.

And may I just parenthetically add how wonderful it is to get a manufacturing question because that is a true sign of progress and success, so thank you for that.

Joe Pantginis: Great. Thanks for all the answers.

Operator: Thank you. I will now turn the call back to Dr. Harith Rajagopalan for closing remarks.

Harith Rajagopalan: Well, thank you very much. Thanks, everyone, for joining us this afternoon. Fractyl Health, Inc. Common Stock has exciting days ahead, with lots of key catalysts coming in the coming months: six-month REVEAL data, six-month midpoint cohort data, one-year data from weight maintenance and REVEAL, pivotal data all coming within the next twelve months. We look forward to sharing updates on our progress, and thank you again.

Operator: This concludes today's conference call. Thank you for participating. You may now disconnect.

This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. Parts of this article were created using Large Language Models (LLMs) based on The Motley Fool's insights and investing approach. It has been reviewed by our AI quality control systems. Since LLMs cannot (currently) own stocks, it has no positions in any of the stocks mentioned. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.

The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.